{"id":10428,"date":"2020-07-30T17:07:37","date_gmt":"2020-07-30T11:37:37","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10428"},"modified":"2021-07-24T12:58:02","modified_gmt":"2021-07-24T07:28:02","slug":"recent-pharma-happenings-for-roche-omega-exevir-gsk","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk","title":{"rendered":"Roche-UCB&#8217;s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08710555d7d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08710555d7d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\/#Roche_bets_USD_120_Million_on_UCBs_anti-tau_Alzheimers_antibody\" >Roche bets USD 120 Million on UCB&#8217;s anti-tau Alzheimer&#8217;s antibody<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\/#%E2%80%98Genome-tuning_biotech_Omega_Therapeutics_snags_USD_85_Million\" >&#8216;Genome-tuning&#8217; biotech Omega Therapeutics snags USD 85 Million&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\/#ExeVir_bags_USD_27_million_to_take_llama-derived_COVID-19_drug_into_the_clinic\" >ExeVir bags USD 27 million to take llama-derived COVID-19 drug into the clinic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\/#GSK_culls_a_host_of_pipeline_meds_after_failures_prioritization\" >GSK culls a host of pipeline meds after failures, prioritization<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_bets_USD_120_Million_on_UCBs_anti-tau_Alzheimers_antibody\"><\/span><strong>Roche bets USD 120 Million on UCB&#8217;s anti-tau Alzheimer&#8217;s antibody<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB&#8217;s anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal&#8217;s total near to USD 2 billion.<\/p>\n\n\n\n<p>The drug, UCB0107, is designed to impede or decrease the buildup of tau proteins in the brain, which leads to nerve cell damage and death. UCB is already developing it for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-market\">progressive supranuclear palsy (PSP)<\/a><\/strong>, an uncommon neurodegenerative disorder, which affects movement, gait, balance, speech, vision, mood and behaviour.<\/p>\n\n\n\n<p>Under the agreement, UCB will fund and carry out a proof-of-concept study in <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer&#8217;s disease<\/a><\/strong>. Once that is done and the data readout, Roche may choose to take over development or hand the rights to the asset back to UCB.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%80%98Genome-tuning_biotech_Omega_Therapeutics_snags_USD_85_Million\"><\/span><strong>&#8216;Genome-tuning&#8217; biotech Omega Therapeutics snags USD 85 Million&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Omega Therapeutics is getting a USD 85 million cash boost. It will push a pipeline of treatments toward the clinic as well as bankroll the recognition of new targets for genomic medicines.<\/p>\n\n\n\n<p>Omega&#8217;s platform is designed to adjust gene expression to healthy levels rather than switching genes on and off.<\/p>\n\n\n\n<p>The work of the company is based on the genes and their regulatory elements found in loops of DNA called Insulated Genomic Domains (IGDs). These loops occur due to long strands of DNA that need to fit into the cell&#8217;s nucleus.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The epigenomic controllers of Omega Therapeutics are designed to target the right place on specific IGDs to restore the function of a gene at the right level.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ExeVir_bags_USD_27_million_to_take_llama-derived_COVID-19_drug_into_the_clinic\"><\/span><strong>ExeVir bags USD 27 million to take llama-derived COVID-19 drug into the clinic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>ExeVir Bio has raised USD 27 million to advance a llama-derived antibody against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a>. The financing that attracted the support of Fund+ and UCB follows research displaying an approach similar to that used by Ablynx can yield single-domain antibodies (VHHs) that neutralize <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">SARS-CoV-2<\/a><\/strong>.<\/p>\n\n\n\n<p>The notable people of Belgian biopharma has come together to get the project underway. VIB, the institute that spawned VHH biotechs Ablynx, Biotalys and Confo Therapeutics, contributed to a paper about the generation of VHHs against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines\"><strong>SARS-CoV-2<\/strong><\/a>. UCB helped make a lead asset based on VIB research and produce clinical batches. And Fund+, which backed Ogeda on route to its \u20ac500 million takeovers by Astellas, led the series A with assists from UCB Ventures, VIB and the Belgian government.<\/p>\n\n\n\n<p>The result is ExeVir, biotech with technology spun off from VIB and \u20ac23 million to take a lead drug into the clinic by the end of the year. That timeline puts ExeVir well behind the front-runners in the race to get an anti-SARS-CoV-2 antibody to market, but the startup and its backers think their VHH approach has advantages.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GSK_culls_a_host_of_pipeline_meds_after_failures_prioritization\"><\/span><strong>GSK culls a host of pipeline meds after failures, prioritization<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>GlaxoSmithKline, the U.S. Big Pharma is selecting five experimental drugs in all, each targeting a different area and for a mixture of reasons.<\/p>\n\n\n\n<p>First up, its <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\"><strong>chronic obstructive pulmonary disease (COPD)<\/strong><\/a> vaccine that is in initial data from its proof-of-concept study showed the primary endpoint was not meeting, and while GSK informed about the work was ongoing to understand the data better and no progression to phase 3 is planned. It is a similar story for GSK&#8217;078 (SARM) for COPD muscle weakness that has been killed off as the data did not bolster the progression in this indication.&nbsp;<\/p>\n\n\n\n<p>And then there are the victims of &#8220;portfolio prioritization,&#8221; namely: GSK&#8217;557 for PI3K delta syndrome, GSK&#8217;394 (combinectin) for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hiv-associated-lipodystrophy-market\"><strong>HIV <\/strong><\/a>and GSK&#8217;091 (a TLR4 agonist) for <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">cancer<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche bets USD 120 Million on UCB&#8217;s anti-tau Alzheimer&#8217;s antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB&#8217;s anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal&#8217;s total near to USD 2 billion. The drug, UCB0107, is designed to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17629,18610,18609,903,349,420,17784,18611,6790,524,2284],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-10428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-covid-19-drug","tag-exevir-bio","tag-gsk","tag-latest-pharma-news","tag-news","tag-omega-therapeutics","tag-progressive-supranuclear-palsy-psp","tag-recent-news","tag-roche","tag-ucb","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roche&#039;s pact; Omega snags $85M; ExeVir bags $27M; GSK axes pipeline<\/title>\n<meta name=\"description\" content=\"The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB&#039;s anti-tau Alzheimer&#039;s antibody development. The drug, UCB0107, is..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s pact; Omega snags $85M; ExeVir bags $27M; GSK axes pipeline\" \/>\n<meta property=\"og:description\" content=\"The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB&#039;s anti-tau Alzheimer&#039;s antibody development. The drug, UCB0107, is..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-30T11:37:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's pact; Omega snags $85M; ExeVir bags $27M; GSK axes pipeline","description":"The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau Alzheimer's antibody development. The drug, UCB0107, is..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk","og_locale":"en_US","og_type":"article","og_title":"Roche's pact; Omega snags $85M; ExeVir bags $27M; GSK axes pipeline","og_description":"The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau Alzheimer's antibody development. The drug, UCB0107, is..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-07-30T11:37:37+00:00","article_modified_time":"2021-07-24T07:28:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk","name":"Roche's pact; Omega snags $85M; ExeVir bags $27M; GSK axes pipeline","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings.jpg","datePublished":"2020-07-30T11:37:37+00:00","dateModified":"2021-07-24T07:28:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau Alzheimer's antibody development. The drug, UCB0107, is..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-omega-exevir-gsk#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings.jpg","width":772,"height":482,"caption":"recent-Pharma-news-and-happenings"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/30170549\/recent-Pharma-news-and-happenings-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID 19 Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ExeVir Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Omega Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Progressive Supranuclear Palsy (PSP)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UCB<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">COVID 19 Drug<\/span>","<span class=\"advgb-post-tax-term\">ExeVir Bio<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Omega Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Progressive Supranuclear Palsy (PSP)<\/span>","<span class=\"advgb-post-tax-term\">recent news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">UCB<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 30, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 30, 2020 5:07 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-Pharma-news-and-happenings","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10428"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10428\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10428"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10428"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}